Wed, February 13, 2013
Tue, February 12, 2013
Mon, February 11, 2013
Sun, February 10, 2013
Fri, February 8, 2013
Thu, February 7, 2013
Wed, February 6, 2013
Tue, February 5, 2013
Mon, February 4, 2013
Sun, February 3, 2013
Sat, February 2, 2013
Fri, February 1, 2013
Thu, January 31, 2013
Wed, January 30, 2013
Tue, January 29, 2013
[ Tue, Jan 29th 2013 ] - Market Wire
AtheroNova Launches New Website
Mon, January 28, 2013
Sun, January 27, 2013
Sat, January 26, 2013
Fri, January 25, 2013
Thu, January 24, 2013

Federman &;; Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against Keryx Biopharmaceutical


//health-fitness.news-articles.net/content/2013/ .. -been-filed-against-keryx-biopharmaceutical.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


February 04, 2013 17:28 ET

Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX)

OKLAHOMA CITY, OK--(Marketwire - Feb 4, 2013) - On February 1, 2013, a class action lawsuit was filed in the United States District Court for the Southern District of New York against Keryx Biopharmaceuticals, Inc. (NASDAQ: [ KERX ]). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is June 1, 2009 through April 1, 2012.

Plaintiff seeks to recover damages on behalf of all Keryx Biopharmaceuticals, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Tuesday, April 2, 2013 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

If you wish to discuss this action, obtain further information and participate in this or any other securities litigation, or should you have any questions or concerns regarding this notice or preservation of your rights, please contact:



Publication Contributing Sources